N2OFF's MitoCareX Bio Study Highlights SLC25A Biomarkers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
N2OFF Inc. shares surged 69.09% in pre-market trading, reaching a 20-day high.
The catalyst for this movement is a new study co-authored by N2OFF's subsidiary MitoCareX Bio, which highlights SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction. This research emphasizes their role in tumor metabolic adaptation and therapy resistance, integrating data from NASA and focusing on the ADP/ATP carrier AAC3, which could advance precision oncology.
This significant research could enhance N2OFF's position in the biotech sector, attracting investor interest and potentially leading to future collaborations or funding opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
